In the specialized field of neurobiology, researchers often require highly consistent, high-purity proteins to model complex pathological processes. When sourcing materials for in vitro studies, alpha synuclein rpeptide has become a benchmark for excellence. As someone who follows advancements in peptide synthesis and recombinant protein technology, I have found that the quality of these reagents is paramount for reproducible experimental outcomes.
Defining the Entity: What is Alpha-Synuclein?
At its core, Alpha-Synuclein (α-Synuclein) is a 14 kD (140 amino acids) acidic presynaptic protein. It is naturally expressed in the brain and is typically a soluble protein under normal physiological conditions. However, the study of its misfolding is a major focus in modern science, as it is a protein central to Parkinson's disease and other neurodegenerative disorders. The prote Recombinant human, native and Mutant Synucleins in is known to form intracellular aggregates, which are often investigated using specialized recombinant forms.
Precision in Recombinant Production
When we discuss recombinant Alpha-Synuclein from rPeptide, we are looking at a product engineered for high monomeric consistency. Whether you are working with Recombinant Human alpha-Synuclein or variants like the A30P Mutant or the A53T mutant, the goal is to achieve a level of purity (o rPeptide - Stratech ften >95%) that eliminates batch-to-batch variability.
* Alpha-Synuclein, A53T Mutant: Frequently used to study familial forms of aggregation.
* Alpha-Synuclein, A30P Mutant: Provides insights into the kinetics of fibrillization.
Alpha-Synuclein, Desalted* Desalted Recombinant Alpha-Synuclein: Ideal for researchers who require a clean baseline for buffer-sensitive assays.
For those investigating structural biology, the availability of specific segments—such as Alpha-Synuclein 1-60, 1-95, 61-140, or 96-140—allows for the mapping of aggregation-prone domains.
Applications in Advanced Research
The utility o Alpha-synuclein (α-synuclein) is a small, acidic protein containing 140 amino acids, highly expressed in the brain and primarily localized in the presynaptic Read more f these proteins extends beyond basic structural analysis. Many labs utilize preformed fibrils of α-synuclein to seed aggregation in cellular models. This is particularly relevant when examining how α-synuclein (α-syn) overload is strongly associated with Parkinson disease.
Furthermore, current efforts made in the development of peptides have led to the creation of novel tools:
1. α-synuclein knockdown peptide: Researchers are exploring ways to modulate protein levels using speci Recombinant Alpha-Synuclein alized sequences like the Tat-βsyn-degron.
2. Human Alpha-synuclein peptide: Often utilized as a synthetic blocking peptide in immunochemical assays.
3. Decoy Peptides: These are being designed to interfere with the pathological conversion of the protein, preventing the formation of cytotoxic species.
Why Quality Matters in Experimental Design
When selecting reagents, I prioritize suppliers that maintain rigorous quality control. The High quality recombinant Alpha-Synuclein, Rabbit and High quality recombinant monkey Alpha-Synuclein offerings illustrate how comparative biology is used to understand cross-species aggregation kinet Recombinant Alpha-Synuclein ics. Because α-synuclein (αSyn) is a protein known to form intracellular aggregates during the manifestation of various pathologies, using a poorly characterized substrate can lead to misleading data.
Whether you are performing Alpha-Synuclein Preformed Fibrils ubiquitin conjugation assays using Recombinant Human alpha-Synuclein as a control substrate or studying the formation of Lewy bodies, the reliability of the starting material is the foundation of the work. The industry standard for these proteins ensures that the 14 kD (140 amino acids) acidic presynaptic protein remains in its intended state—whether that is a monomeric form for structural studies or a fibrillar form for seeding experiments.
By adhering to strict manufacturing standards, providers make it possible for the scientific community to advance our understanding of how this protein behaves, interacts, and eventually, how we might one day effectively target its pathological pathways.